GT Medical Technologies has announced the appointment of James Leech as its new Chief Financial and Strategy Officer, marking a pivotal step in the company’s mission to expand access to its groundbreaking brain tumor treatment, GammaTile®. With over a decade of experience in commercial-stage healthcare companies, Mr. Leech brings a strategic blend of financial expertise and operational leadership. His proven track record in scaling life sciences ventures positions him well to guide GT Medical Technologies through its next phase of growth and market expansion.

In his new role, Mr. Leech will oversee corporate strategy, investor relations, and financial operations, working closely with the leadership team to accelerate the adoption of GammaTile across clinical settings. His responsibilities also include identifying strategic partnerships and optimizing commercial opportunities to extend the reach of the FDA-cleared GammaTile platform. This bioresorbable radiotherapy implant is used during brain tumor removal surgery to deliver immediate, localized radiation to the tumor site, minimizing treatment delays and enhancing patient outcomes.

As the company continues to advance its goal of improving the lives of patients with brain tumors, Mr. Leech’s cross-sector and cross-border experience in MedTech, biopharma, and healthcare services will be critical. His leadership is expected to help scale the impact of GammaTile both domestically and internationally, reinforcing GT Medical Technologies' position as a leader in innovative, patient-centric neuro-oncology solutions.